FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097133079> ?p ?o ?g. }

• W3097133079 endingPage "7" @default.
• W3097133079 startingPage "6" @default.
• W3097133079 abstract "Large-scale next-generation sequencing (NGS) studies have suggested common patterns of co-occurrence or mutual exclusivity between genetic alterations in chronic lymphocytic leukemia (CLL). However, little is known about how most of these alterations cooperate to drive CLL pathogenesis, as well as the impact of these concurrencies in clinical outcome. In this regard, we investigated the clinical and biological impact of the co-occurrence of high-risk lesions such as del(11q)/ATM mutation and del(17p)/TP53 mutation by integrating NGS and CRISPR/Cas9 approaches. To address these questions, we first analyzed the mutational profile of 271 CLLs (17.3% del(11q); 10.7% del(17p)). The most frequently mutated genes were NOTCH1 (20%), TP53 (14%), SF3B1 (11%) and ATM (10%). Within del(11q), 32% showed TP53 alterations (53% biallelic; 47% monoallelic). Interestingly, patients harboring combined del(11q) and TP53 alterations by either mutation or deletion (del(11q) TP53ALT) exhibited significantly shorter overall survival (OS) than del(11q) CLLs without TP53 alterations (del(11q) TP53WT) and those TP53 altered without del(11q) (no del(11q) TP53ALT) (median 17 vs. 88, 36 months; P=0.0004, P=0.02). Conversely, we observed a significant lack of ATM mutations in CLLs with biallelic TP53 alterations (P=0.002) and a mutual exclusivity between biallelic TP53 and biallelic ATM losses (P=0.03)(Fig 1A). Based on the NGS results, we next used the CRISPR/Cas9 system to model monoallelic and biallelic ATM and TP53 loss in vitro. We generated isogenic HG3-Cas9 CLL-derived cell lines harboring monoallelic del(11q) (targeting 11q22.1/11q23.3 regions) and further loss-of-function mutations in ATM and/or TP53 to mimic all the possible combinations observed in our CLL cohort. By proliferation assays, we noted that the introduction of TP53 mutations increased the proliferation rates in both HG3WT and HG3-del(11q) cells. In contrast, the introduction of an ATM truncating mutation on the remaining allele of the HG3-del(11q) TP53MUT clone, suppressed this proliferative advantage, with growth rates comparable to those of HG3-del(11q). Accordingly, DNA content analysis by propidium iodide revealed that cells harboring biallelic ATM and TP53 loss also showed mitotic and cell cycle defects. To further evaluate the implications of these alterations in the clonal dynamics of CLL in vivo, we performed fluorescence-based clonal competition experiments by injecting these edited cell lines intravenously into NGS mice. First, we observed that HG3-TP53MUT cells outgrew HG3WT cells in spleen of xenotransplanted mice 14 days after injection (P&lt;0.001). In a second experiment, HG3-del(11q), HG3-del(11q) TP53MUT and HG3-del(11q) ATMMUTTP53MUT cells were injected. Strikingly, HG3-del(11q) TP53MUT cells were able to outcompete HG3-del(11q) cells in spleen and bone marrow (P&lt;0.001; P&lt;0.001). By contrast, HG3-del(11q) ATMMUTTP53MUT cells failed to engraft neither in spleen nor bone marrow, being outcompeted by the other injected cells (P&lt;0.001), providing biological insights on the mutual exclusivity of these genetic events in CLL (Fig 1B). We next assessed whether these cell models could predict responses of these combined abnormalities to BTK and PI3K inhibitors. We observed that HG3-del(11q) TP53MUT and HG3-TP53MUT cells showed partial response to ibrutinib and idelalisib, although the IC50 values were still higher than the ones observed in HG3WT clones, especially with idelalisib (27.4 and 20.6 vs. 1.8 uM, respectively). Nonetheless, we found that HG3-del(11q) TP53MUT cells were highly sensitive to novel preclinical drugs that have been shown to be effective in TP53 deficient cells such ATR inhibitors, with an IC50 value comparable to HG3WT cells (mean IC50 0.55 vs. 0.67 uM) (Fig 1C). In summary, we show that mutations in TP53 can appear in a subset of monoallelic del(11q) CLL cases, conferring a synergistic clonal advantage in vivo, and therefore a dismal clinical impact on the OS of this CLL subgroup. In addition, the biological basis of mutual exclusivity of biallelic ATM and TP53 alterations in CLL was assessed, underscoring the importance of the number of alleles affected by these alterations, and establishing novel pre-clinical models for the study of the biology and therapeutic response of concurrent genetic abnormalities in the disease. Funding: PI18/01500 FI19/00191 CD19/00222 *MQA CPC equal contr Disclosures No relevant conflicts of interest to declare." @default.
• W3097133079 created "2020-11-09" @default.
• W3097133079 creator A5022013234 @default.
• W3097133079 creator A5029088164 @default.
• W3097133079 creator A5034771058 @default.
• W3097133079 creator A5035896968 @default.
• W3097133079 creator A5040387233 @default.
• W3097133079 creator A5048683667 @default.
• W3097133079 creator A5050004865 @default.
• W3097133079 creator A5055033732 @default.
• W3097133079 creator A5059408277 @default.
• W3097133079 creator A5059635260 @default.
• W3097133079 creator A5060880185 @default.
• W3097133079 creator A5061553190 @default.
• W3097133079 creator A5064854422 @default.
• W3097133079 creator A5074746066 @default.
• W3097133079 creator A5080348867 @default.
• W3097133079 creator A5085470464 @default.
• W3097133079 creator A5087073396 @default.
• W3097133079 date "2020-11-05" @default.
• W3097133079 modified "2023-10-16" @default.
• W3097133079 title "Clinical and Biological Impact of TP53 Alterations in Del(11q) Chronic Lymphocytic Leukemia" @default.
• W3097133079 doi "https://doi.org/10.1182/blood-2020-141015" @default.
• W3097133079 hasPublicationYear "2020" @default.
• W3097133079 type Work @default.
• W3097133079 sameAs 3097133079 @default.
• W3097133079 citedByCount "1" @default.
• W3097133079 countsByYear W30971330792021 @default.
• W3097133079 crossrefType "journal-article" @default.
• W3097133079 hasAuthorship W3097133079A5022013234 @default.
• W3097133079 hasAuthorship W3097133079A5029088164 @default.
• W3097133079 hasAuthorship W3097133079A5034771058 @default.
• W3097133079 hasAuthorship W3097133079A5035896968 @default.
• W3097133079 hasAuthorship W3097133079A5040387233 @default.
• W3097133079 hasAuthorship W3097133079A5048683667 @default.
• W3097133079 hasAuthorship W3097133079A5050004865 @default.
• W3097133079 hasAuthorship W3097133079A5055033732 @default.
• W3097133079 hasAuthorship W3097133079A5059408277 @default.
• W3097133079 hasAuthorship W3097133079A5059635260 @default.
• W3097133079 hasAuthorship W3097133079A5060880185 @default.
• W3097133079 hasAuthorship W3097133079A5061553190 @default.
• W3097133079 hasAuthorship W3097133079A5064854422 @default.
• W3097133079 hasAuthorship W3097133079A5074746066 @default.
• W3097133079 hasAuthorship W3097133079A5080348867 @default.
• W3097133079 hasAuthorship W3097133079A5085470464 @default.
• W3097133079 hasAuthorship W3097133079A5087073396 @default.
• W3097133079 hasConcept C104317684 @default.
• W3097133079 hasConcept C2777938653 @default.
• W3097133079 hasConcept C2778461978 @default.
• W3097133079 hasConcept C501734568 @default.
• W3097133079 hasConcept C502942594 @default.
• W3097133079 hasConcept C54355233 @default.
• W3097133079 hasConcept C86803240 @default.
• W3097133079 hasConcept C98108389 @default.
• W3097133079 hasConceptScore W3097133079C104317684 @default.
• W3097133079 hasConceptScore W3097133079C2777938653 @default.
• W3097133079 hasConceptScore W3097133079C2778461978 @default.
• W3097133079 hasConceptScore W3097133079C501734568 @default.
• W3097133079 hasConceptScore W3097133079C502942594 @default.
• W3097133079 hasConceptScore W3097133079C54355233 @default.
• W3097133079 hasConceptScore W3097133079C86803240 @default.
• W3097133079 hasConceptScore W3097133079C98108389 @default.
• W3097133079 hasIssue "Supplement 1" @default.
• W3097133079 hasLocation W30971330791 @default.
• W3097133079 hasOpenAccess W3097133079 @default.
• W3097133079 hasPrimaryLocation W30971330791 @default.
• W3097133079 hasRelatedWork W1562693820 @default.
• W3097133079 hasRelatedWork W1895018249 @default.
• W3097133079 hasRelatedWork W2025965695 @default.
• W3097133079 hasRelatedWork W2032200822 @default.
• W3097133079 hasRelatedWork W2068588654 @default.
• W3097133079 hasRelatedWork W2077190448 @default.
• W3097133079 hasRelatedWork W2135257384 @default.
• W3097133079 hasRelatedWork W2384774992 @default.
• W3097133079 hasRelatedWork W3173461521 @default.
• W3097133079 hasRelatedWork W4315629143 @default.
• W3097133079 hasVolume "136" @default.
• W3097133079 isParatext "false" @default.
• W3097133079 isRetracted "false" @default.
• W3097133079 magId "3097133079" @default.
• W3097133079 workType "article" @default.